Related Experiment Videos
NovoSeven in immune tolerance therapy.
H H Brackmann1, E Effenberger, L Hess
1Haemophilia Centre, Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn University, Germany.
Summary
For haemophilia patients with inhibitors, on-demand recombinant activated factor VII (rFVIIa) effectively lowers inhibitor titres before immune tolerance therapy (ITT). This approach optimizes treatment conditions for ITT success.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Development of inhibitors is a significant challenge in haemophilia treatment.
- Factor concentrates and treatment regimens impact inhibitor titre levels.
Purpose of the Study:
- To investigate the effect of factor concentrate and treatment regimen on inhibitor titre levels in haemophilia patients.
- To evaluate the efficacy of different treatment strategies prior to immune tolerance therapy (ITT).
Main Methods:
- Study included nine patients with haemophilia A or B and inhibitors.
- Patients were categorized based on treatment: on-demand rFVIIa, prophylactic aPCC with rFVIIa, or rFVIIa prophylaxis with aPCC/rFVIIa.
- Inhibitor titre levels were monitored over time.
Main Results:
- On-demand rFVIIa therapy was effective and safe for acute bleeding.
- Inhibitor titres decreased significantly in patients treated with on-demand rFVIIa prior to ITT.
- Prophylactic rFVIIa in one group did not yield favorable results, possibly due to its short half-life.
Conclusions:
- Exclusive use of on-demand rFVIIa before ITT is effective in reducing inhibitor titres.
- This strategy optimizes conditions for successful ITT in haemophilia patients with inhibitors.